Pharma Manufacturing & CDMO

1.0Market Snapshot

CHF ~80B+: Swiss pharmaceutical exports exceed CHF 80 billion annually, making Switzerland the world's largest per-capita pharma exporter (Swiss Federal Customs). The domestic pharma manufacturing sector (including CDMOs, API producers, and equipment manufacturers) generates approximately CHF 25-30B in value-added
~1,200: Pharma, biotech, and medtech manufacturing companies in Switzerland including CDMOs, API producers, drug substance/product manufacturers, and specialized equipment firms (Swiss Biotech Association, Interpharma)
~48,000: Total employment in Swiss pharmaceutical manufacturing, including production operators, quality assurance/control, process engineers, and regulatory affairs specialists (Interpharma, BFS NOGA 21). The broader pharma/biotech sector employs ~50,000 in R&D and commercial roles additionally
~95%: The Swiss pharmaceutical industry is the most export-oriented sector of the economy. Over 95% of production is exported, primarily to the EU, US, and Asian markets (Interpharma annual report)
+6.5%: Annual growth rate of Swiss pharma manufacturing output, driven by the shift to biologics and cell/gene therapy, CDMO capacity expansion, and post-COVID reshoring of API production to Europe. Biologics manufacturing is growing at 10-12% annually

2.0Industry Overview

Market Scope

Switzerland is the undisputed global capital of pharmaceutical manufacturing, with the Basel region serving as the epicenter of an industry that has defined the country's economic identity for over a century. The sector's dominance is extraordinary: pharma accounts for approximately 40% of all Swiss exports, and Switzerland is the world's largest per-capita pharmaceutical exporter. This preeminence is anchored by two of the world's largest pharma companies -- Roche (CHF 60B revenue) and Novartis (CHF 45B revenue) -- both headquartered in Basel, along with Lonza Group (CHF 6.7B revenue), the world's largest contract development and manufacturing organization (CDMO).

3.0Industry Health Check (SWOT)

Key opportunityBiologics manufacturing boom

Key riskAsian CDMO competition

Internal factors

Strengths5

Unrivaled pharma cluster: Basel hosts Roche, Novartis, Lonza, and hundreds of specialized suppliers, creating the world's densest pharmaceutical ecosystem with unmatched talent pools and knowledge spillovers

Weaknesses5

Highest manufacturing costs in Europe: Swiss wages for GMP-qualified staff (CHF 90,000-150,000 for operators, CHF 150,000-250,000 for engineers) are 30-50% above EU competitors (Ireland, Singapore)→ §5.0

External factors

Opportunities5

Biologics manufacturing boom: the shift from small-molecule to biologic drugs (now ~40% of new approvals) creates massive demand for mammalian cell culture and microbial fermentation capacity

Threats5

Asian CDMO competition: Samsung Biologics, WuXi Biologics, and Indian API manufacturers offer 30-50% cost advantages, pressuring Swiss CDMOs on price-sensitive commodity manufacturing→ §5.0

Sector Outlook

DefensiveBalancedGrowth

4.0Key Trends

Biologics & Large-Molecule Manufacturing Shift

40%

The pharmaceutical industry is undergoing a fundamental shift from small-molecule chemical drugs to large-molecule biologics (monoclonal antibodies, fusion proteins, ADCs). Biologics now account for approximately 40% of new drug approvals and are growing to represent over 50% of global pharma revenue. This shift has profound implications for manufacturing: biologic production requires complex mammalian cell culture or microbial fermentation facilities that cost CHF 200-500 million to build and take 4-6 years from planning to GMP validation. Lonza's Visp and Basel sites are at the epicenter of this trend, with ongoing capacity expansions including new single-use bioreactor trains and continuous manufacturing lines. Swiss CDMOs are uniquely positioned due to their established regulatory track records with Swissmedic, FDA, and EMA. The capacity constraint is real: global biologics manufacturing capacity utilization exceeds 85%, creating a structural seller's market for qualified CDMOs.

Cell & Gene Therapy Manufacturing

CHF 30

Cell and gene therapies (CGT) represent the next frontier in pharmaceutical manufacturing, with over 2,000 CGT clinical trials globally and a market projected to reach CHF 30-40 billion by 2030. These therapies require fundamentally different manufacturing approaches: autologous therapies (patient-specific) demand flexible, small-batch cleanroom facilities, while allogeneic therapies (off-the-shelf) require scalable production platforms. Lonza has invested over CHF 500 million in CGT manufacturing capacity in Houston (USA) and is expanding European capabilities. Swiss cleanroom equipment maker Skan AG (Allschwil) provides critical isolator technology for aseptic CGT production. The regulatory complexity of CGT manufacturing -- combining drug and biological product requirements -- creates additional moats for experienced Swiss manufacturers. For M&A investors, smaller Swiss biotech firms with GMP-validated CGT manufacturing capabilities are highly attractive acquisition targets valued at premium multiples.

Peptide Manufacturing Renaissance

20%

The GLP-1 receptor agonist revolution (Novo Nordisk's Ozempic/Wegovy, Eli Lilly's Mounjaro/Zepbound) has triggered an unprecedented demand surge for peptide API manufacturing. The global peptide therapeutics market is growing at 15-20% annually, and Bachem (Bubendorf, BL) -- the world's largest independent peptide manufacturer -- is the primary beneficiary. Bachem has announced CHF 800 million+ in capacity expansion investments through 2026, including new production buildings in Bubendorf and expansion of its US facility in Vista, California. The company's share price has tripled since 2020, reflecting the structural growth in peptide demand. Other Swiss players in the peptide value chain include PolyPeptide Group and various specialized chemical suppliers. The trend extends beyond GLP-1s: peptide-drug conjugates, cyclic peptides, and peptide-based vaccines are expanding the addressable market. Swiss peptide manufacturers benefit from decades of accumulated process chemistry expertise and validated GMP facilities.

Pharma Equipment & Cleanroom Technology

25%

Behind every pharmaceutical manufacturing facility stands a sophisticated ecosystem of equipment suppliers, cleanroom specialists, and qualification/validation service providers. Switzerland hosts world-leading companies in this 'infrastructure layer' of pharma manufacturing. Skan AG (Allschwil, BL) is the global leader in isolator and containment technology for aseptic processing, with a dominant market position in high-potency API handling and sterile filling equipment. The company listed on SIX in 2021 and has grown rapidly on the back of CGT and biologics facility demand. Other Swiss pharma equipment specialists include Syntegon (formerly Bosch Packaging, with Swiss operations), various cleanroom construction firms, and a cluster of pharma engineering and validation consultancies in the Basel area. The pharma equipment segment offers attractive margins (15-25% EBITDA) and benefits from the same secular growth drivers as the broader manufacturing sector without the complexity of GMP product manufacturing.

5.0Cost Structure Benchmark

27%

32%

17%

10%

Raw Materials & APIs27%: active ingredients, excipients, media
Personnel32%: highly skilled: operators, engineers, QA/QC
Equipment Depreciation & Maintenance17%: bioreactors, fill/finish
Quality & Compliance10%: validation, documentation, audits
Energy & Utilities4%: cleanrooms, HVAC, purified water, steam
EBITDA Margin10%

Based on a typical Swiss CDMO manufacturing biologics or chemical APIs. Personnel costs dominate due to the highly skilled workforce required for GMP-compliant production (Swissmedic/FDA-audited facilities). Equipment depreciation reflects the capital-intensive nature of pharma manufacturing: a single bioreactor train costs CHF 50-100M, and fill/finish lines CHF 30-80M. Quality and compliance costs are substantially higher than in other manufacturing sectors due to extensive documentation, batch record review, stability testing, and regulatory audit preparation. EBITDA margins vary significantly by segment: contract manufacturing of commodity APIs earns 5-8%, while specialized biologics CDMO work commands 15-25% EBITDA margins. Equipment/cleanroom suppliers like Skan achieve 18-25% EBITDA. Peptide manufacturing (Bachem model) achieves 25-30% EBITDA due to extreme specialization and capacity scarcity.

6.0Key Swiss Players

Name	Location	Key Facts
Lonza Group AG	Basel BS / Visp VS	CHF 6.7B revenue, ~17,000 employees. World's largest CDMO (contract development and manufacturing organization). Core segments: Biologics (mammalian cell culture, microbial fermentation), Small Molecules (chemical APIs), and Cell & Gene (CGT manufacturing). Flagship manufacturing complex in Visp (VS) is one of the world's largest biologics production sites. Listed on SIX (market cap ~CHF 30B). Key clients include most top-20 pharma companies.
Siegfried Holding AG	Zofingen AG	CHF ~1.3B revenue, ~3,700 employees. Leading CDMO for drug substances (chemical APIs) and drug products (finished dosage forms). 10 manufacturing sites worldwide including Zofingen (CH), Evionnaz (VS), and Minden (DE). Growth strategy through acquisitions (Hameln Pharma, BASF sites). Strong in complex chemical synthesis, sterile fill/finish, and spray-drying. Listed on SIX.
Bachem Holding AG	Bubendorf BL	CHF ~800M revenue, ~2,000 employees. Global leader in peptide and oligonucleotide manufacturing -- the undisputed 'king of peptides.' Beneficiary of GLP-1 agonist boom (Ozempic, Mounjaro). CHF 800M+ capacity expansion investment through 2026. Production sites in Bubendorf (CH), Vionnaz (CH), Vista CA (US), and Sukagawa (JP). Listed on SIX. EBITDA margins of 25-30% reflecting extreme specialization.
Skan AG	Allschwil BL	CHF ~320M revenue, ~1,000 employees. Global market leader in isolators, cleanroom equipment, and containment solutions for aseptic pharmaceutical manufacturing. Products include barrier systems for sterile filling, high-potency API handling, and cell/gene therapy production. Listed on SIX since 2021. EBITDA margin ~20%. Benefits from every new pharma facility build globally.
Cilag AG (Johnson & Johnson)	Schaffhausen SH	Major pharmaceutical manufacturing site operated by Johnson & Johnson in Schaffhausen. One of J&J's largest global production facilities, manufacturing APIs and finished dosage forms for Janssen pharmaceutical products. ~2,500 employees. Produces treatments across oncology, immunology, and neuroscience. Significant recent investments in biologics manufacturing capacity.
Novartis Technical Operations	Stein AG / Basel BS	Novartis (CHF 45B group revenue) operates major manufacturing sites across Switzerland including Stein (AG), Schweizerhalle (BL), and the historic Basel campus. Swiss manufacturing sites focus on chemical APIs, solid oral dosage forms, and increasingly gene therapy products (Zolgensma). ~10,000 employees in Swiss manufacturing operations. Novartis is spinning off significant manufacturing assets as part of its portfolio refocusing.
Roche Manufacturing	Kaiseraugst AG / Basel BS	Roche (CHF 60B group revenue) operates pharmaceutical and diagnostic manufacturing facilities in Basel (Kaiseraugst), with major investments in biologics production. The Kaiseraugst site is one of Europe's most advanced biologics manufacturing campuses. Roche is one of the world's largest producers of monoclonal antibodies (Herceptin, Avastin, Rituxan). ~8,000 employees in Swiss manufacturing.
Celgene/BMS Manufacturing (Couvet)	Couvet NE	Bristol-Myers Squibb (acquired Celgene 2019) operates a significant pharmaceutical manufacturing site in Couvet, Canton Neuchatel. The facility specializes in API manufacturing for key BMS/Celgene products including immunomodulatory drugs. ~400 employees. One of the few major pharma manufacturing sites in Romandie, contributing to economic diversity beyond the Basel cluster.

Lonza Group AG

Basel BS / Visp VS

CHF 6.7B revenue, ~17,000 employees. World's largest CDMO (contract development and manufacturing organization). Core segments: Biologics (mammalian cell culture, microbial fermentation), Small Molecules (chemical APIs), and Cell & Gene (CGT manufacturing). Flagship manufacturing complex in Visp (VS) is one of the world's largest biologics production sites. Listed on SIX (market cap ~CHF 30B). Key clients include most top-20 pharma companies.

Siegfried Holding AG

Zofingen AG

CHF ~1.3B revenue, ~3,700 employees. Leading CDMO for drug substances (chemical APIs) and drug products (finished dosage forms). 10 manufacturing sites worldwide including Zofingen (CH), Evionnaz (VS), and Minden (DE). Growth strategy through acquisitions (Hameln Pharma, BASF sites). Strong in complex chemical synthesis, sterile fill/finish, and spray-drying. Listed on SIX.

Bachem Holding AG

Bubendorf BL

CHF ~800M revenue, ~2,000 employees. Global leader in peptide and oligonucleotide manufacturing -- the undisputed 'king of peptides.' Beneficiary of GLP-1 agonist boom (Ozempic, Mounjaro). CHF 800M+ capacity expansion investment through 2026. Production sites in Bubendorf (CH), Vionnaz (CH), Vista CA (US), and Sukagawa (JP). Listed on SIX. EBITDA margins of 25-30% reflecting extreme specialization.

Skan AG

Allschwil BL

CHF ~320M revenue, ~1,000 employees. Global market leader in isolators, cleanroom equipment, and containment solutions for aseptic pharmaceutical manufacturing. Products include barrier systems for sterile filling, high-potency API handling, and cell/gene therapy production. Listed on SIX since 2021. EBITDA margin ~20%. Benefits from every new pharma facility build globally.

Cilag AG (Johnson & Johnson)

Schaffhausen SH

Major pharmaceutical manufacturing site operated by Johnson & Johnson in Schaffhausen. One of J&J's largest global production facilities, manufacturing APIs and finished dosage forms for Janssen pharmaceutical products. ~2,500 employees. Produces treatments across oncology, immunology, and neuroscience. Significant recent investments in biologics manufacturing capacity.

Novartis Technical Operations

Stein AG / Basel BS

Novartis (CHF 45B group revenue) operates major manufacturing sites across Switzerland including Stein (AG), Schweizerhalle (BL), and the historic Basel campus. Swiss manufacturing sites focus on chemical APIs, solid oral dosage forms, and increasingly gene therapy products (Zolgensma). ~10,000 employees in Swiss manufacturing operations. Novartis is spinning off significant manufacturing assets as part of its portfolio refocusing.

Roche Manufacturing

Kaiseraugst AG / Basel BS

Roche (CHF 60B group revenue) operates pharmaceutical and diagnostic manufacturing facilities in Basel (Kaiseraugst), with major investments in biologics production. The Kaiseraugst site is one of Europe's most advanced biologics manufacturing campuses. Roche is one of the world's largest producers of monoclonal antibodies (Herceptin, Avastin, Rituxan). ~8,000 employees in Swiss manufacturing.

Celgene/BMS Manufacturing (Couvet)

Couvet NE

Bristol-Myers Squibb (acquired Celgene 2019) operates a significant pharmaceutical manufacturing site in Couvet, Canton Neuchatel. The facility specializes in API manufacturing for key BMS/Celgene products including immunomodulatory drugs. ~400 employees. One of the few major pharma manufacturing sites in Romandie, contributing to economic diversity beyond the Basel cluster.

7.0Succession & M&A Context

Succession & M&A in Pharma Manufacturing

8-12x: Typical EBITDA multiple for CDMO platforms
15-20x: Premium EBITDA multiple (biologics/peptide specialists)
~1,200: Pharma/biotech manufacturing companies in Switzerland
3-5 yrs: Time to obtain Swissmedic manufacturing license

The pharma manufacturing and CDMO sector presents one of the most attractive succession and M&A landscapes in the Swiss economy, characterized by high barriers to entry, structural growth tailwinds, and premium valuations. Unlike general manufacturing, pharma production assets carry unique value anchored in their GMP compliance status: a Swissmedic-licensed facility with validated processes, established quality systems, and a clean inspection history represents 3-5 years of regulatory work and CHF 50-200 million in investment that cannot be easily replicated. This creates a powerful 'regulatory moat' that supports elevated transaction multiples. The sector's succession dynamics differ from traditional SME sectors: while some smaller CDMOs and API manufacturers face classic family succession challenges, the primary M&A driver is strategic consolidation by larger CDMOs (Lonza, Siegfried, Catalent) seeking to add manufacturing capacity, technology platforms, or geographic coverage. Private equity firms specializing in healthcare (including Blackstone, EQT, and Permira) are also active acquirers, attracted by the predictable contract revenue streams, high customer switching costs (revalidation takes 12-18 months), and secular growth in outsourced pharma manufacturing. Valuation multiples are the highest of any manufacturing sector: 8-12x EBITDA is standard for CDMO platforms, rising to 15-20x for specialized biologics or peptide manufacturing with demonstrated growth trajectories. Even smaller GMP-licensed contract labs and niche API manufacturers command 6-10x EBITDA given the regulatory barriers.

8.0Regional Clusters

Basel-Stadt & Baselland

BSBL

The undisputed global capital of pharmaceutical manufacturing. Home to Roche (Kaiseraugst), Novartis (Basel, Schweizerhalle), Lonza Group headquarters, Skan AG (Allschwil), Bachem (Bubendorf), and hundreds of specialized pharma suppliers and contract manufacturers. The 'Basel pharma cluster' generates approximately 70% of Swiss pharma manufacturing value. The University of Basel, ETH Department of Biosystems, and the Friedrich Miescher Institute provide world-class research. Historical cradle of the Swiss pharma industry: Ciba, Geigy, and Sandoz (all founded in Basel in the 19th century) spawned today's Novartis and the broader Basel pharma ecosystem.

Visp, Valais

Home to Lonza's flagship biologics manufacturing complex, one of the largest mammalian cell culture production sites in the world. The Visp site has expanded continuously since the 1990s and now spans multiple large-scale production buildings for biologics, cell therapy, and chemical API manufacturing. Lonza employs approximately 4,000 people in Visp, making it the region's largest employer. Siegfried also operates a manufacturing site in Evionnaz (VS). The Valais location offers advantages including hydroelectric power (lower energy costs), available land for expansion, and competitive wage levels compared to Basel.

Zofingen & Aargau

Siegfried Holding AG, one of Switzerland's leading CDMOs, is headquartered in Zofingen with major chemical API and drug product manufacturing facilities. The Aargau region also hosts Novartis Technical Operations in Stein and various pharma service companies. DOTTIKON ES (Dottikon, AG) manufactures fine chemicals and pharmaceutical intermediates using hazardous chemical reactions, serving as a niche CDMO for complex synthesis. The region benefits from excellent logistics connections (A1 motorway, rail) and proximity to both Basel and Zurich labor markets.

Bubendorf & Surrounding

Bachem Holding AG's global headquarters and primary peptide manufacturing facility in Bubendorf (BL) has made this small Baselland municipality a globally significant pharma manufacturing hub. As the 'king of peptides,' Bachem's massive capacity expansion (CHF 800M+) is transforming the site into one of the world's largest peptide API production centers. The region benefits from proximity to the Basel pharma cluster while offering more available land and lower costs than Basel-Stadt. PolyPeptide Group also has Swiss operations contributing to the peptide manufacturing concentration.

Market Pulse

Unlock full Pharma Manufacturing & CDMO intelligence

Key players, succession analysis, and regional clusters for Pharma Manufacturing & CDMO — subscribe free to Market Pulse.

Free weekly newsletter. Unsubscribe anytime.

Sources

Interpharma - Association of Research-Based Pharmaceutical Companies in Switzerland Swiss Biotech Association - Industry Reports Lonza Group AG - Annual Report & Company Overview Bachem Holding AG - Investor Relations Siegfried Holding AG - Annual Report Skan AG - Company Overview Swissmedic - Swiss Agency for Therapeutic Products Swiss Federal Customs - Trade Statistics (Pharma Exports)Swiss Federal Statistical Office - Pharmaceutical Industry scienceindustries - Swiss Chemical, Pharma & Biotech Association

ValIndex Intelligence · Alain Walder, M.A. HSG|Data as of 2026-02|10 sources cited

9.0Frequently Asked Questions

▶How much is a Pharma Manufacturing & CDMO company worth in Switzerland?

The average Swiss Pharma Manufacturing & CDMO company is valued at 6.0 - 8.0× EBITDA on a statutory (tax-based) basis and 8.0 - 12.0× EBITDA in actual deal transactions. The spread between statutory and deal multiples represents a key arbitrage opportunity for informed buyers. The current market trend is rising, with an arbitrage gap rated as high. Actual valuations depend heavily on recurring revenue share, customer diversification, management depth, and equipment modernity.

▶What factors affect the valuation of a Pharma Manufacturing & CDMO company?

Key valuation drivers include: Unrivaled pharma cluster: Basel hosts Roche, Novartis, Lonza, and hundreds of specialized suppliers, creating the world's densest pharmaceutical ecosystem with unmatched talent pools and knowledge spillovers; GMP regulatory moat: Swissmedic manufacturing licenses take 3-5 years to obtain and require CHF 50-200M investment, creating extraordinary barriers to entry that protect incumbent manufacturers. Factors that can compress valuations include: Highest manufacturing costs in Europe: Swiss wages for GMP-qualified staff (CHF 90,000-150,000 for operators, CHF 150,000-250,000 for engineers) are 30-50% above EU competitors (Ireland, Singapore); Acute talent shortage: ~2,000-3,000 unfilled positions in pharma manufacturing, particularly for bioprocess engineers, quality assurance specialists, and regulatory affairs experts. Deal multiples typically range from 8.0 - 12.0× EBITDA, but actual prices vary significantly based on customer concentration, management quality, revenue predictability, and geographic reach within Switzerland's 26 cantons.

▶How many Pharma Manufacturing & CDMO companies are there in Switzerland?

Approximately ~1,200 companies operate in Switzerland's Pharma Manufacturing & CDMO sector. Pharma, biotech, and medtech manufacturing companies in Switzerland including CDMOs, API producers, drug substance/product manufacturers, and specialized equipment firms (Swiss Biotech Association, Interpharma) The sector employs ~48,000 people and represents a market of CHF ~80B+. Company counts have been evolving due to consolidation trends and succession-driven market exits across Swiss SME sectors.

▶What is the succession situation for Pharma Manufacturing & CDMO in Switzerland?

▶What are the key market trends in Swiss Pharma Manufacturing & CDMO?

The 4 key trends shaping Swiss Pharma Manufacturing & CDMO are: (1) Biologics & Large-Molecule Manufacturing Shift; (2) Cell & Gene Therapy Manufacturing; (3) Peptide Manufacturing Renaissance; (4) Pharma Equipment & Cleanroom Technology. The pharmaceutical industry is undergoing a fundamental shift from small-molecule chemical drugs to large-molecule biologics (monoclonal antibodies, fusion proteins, ADCs). Biologics now account for a... These trends directly impact company valuations and M&A activity in the sector.

▶What are the key risks when buying a Pharma Manufacturing & CDMO company?

The principal acquisition risks are: (1) Asian CDMO competition: Samsung Biologics, WuXi Biologics, and Indian API manufacturers offer 30-50% cost advantages, pressuring Swiss CDMOs on price-sensitive commodity manufacturing; (2) US Biosecure Act: while potentially benefiting Swiss CDMOs by restricting Chinese competitors, could also create uncertainty and disrupt established supply chains involving Swiss-Chinese partnerships; (3) Swissmedic regulatory divergence from EU: loss of automatic EU mutual recognition could complicate market access for Swiss-manufactured products and increase dual-filing costs. Buyers should conduct thorough due diligence on customer concentration, regulatory compliance, and key-person dependencies. Deal multiples of 8.0 - 12.0× EBITDA may be discounted for firms with elevated risk profiles.

▶What is the typical cost structure for Swiss Pharma Manufacturing & CDMO companies?

The typical cost breakdown for a Swiss Pharma Manufacturing & CDMO firm is: Raw Materials & APIs (active ingredients, excipients, media): 27%, Personnel (highly skilled: operators, engineers, QA/QC): 32%, Equipment Depreciation & Maintenance (bioreactors, fill/finish): 17%, Quality & Compliance (validation, documentation, audits): 10%, Energy & Utilities (cleanrooms, HVAC, purified water, steam): 4%, EBITDA Margin: 10%. Based on a typical Swiss CDMO manufacturing biologics or chemical APIs. Personnel costs dominate due to the highly skilled workforce required for GMP-compliant production (Swissmedic/FDA-audited facilities). Equipment depreciation reflects the capital-intensive nature of pharma manufacturing: a single bioreactor train costs CHF 50-100M, and fill/finish lines CHF 30-80M. Quality and compliance costs are substantially higher than in other manufacturing sectors due to extensive documentation, batch record review, stability testing, and regulatory audit preparation. EBITDA margins vary significantly by segment: contract manufacturing of commodity APIs earns 5-8%, while specialized biologics CDMO work commands 15-25% EBITDA margins. Equipment/cleanroom suppliers like Skan achieve 18-25% EBITDA. Peptide manufacturing (Bachem model) achieves 25-30% EBITDA due to extreme specialization and capacity scarcity. These benchmarks are important for buyers assessing operational efficiency and margin improvement potential post-acquisition.

▶Which regions are the main Pharma Manufacturing & CDMO clusters in Switzerland?

Switzerland's main Pharma Manufacturing & CDMO clusters are: (1) Basel-Stadt & Baselland (BS, BL); (2) Visp, Valais (VS); (3) Zofingen & Aargau (AG); (4) Bubendorf & Surrounding (BL). The undisputed global capital of pharmaceutical manufacturing. Home to Roche (Kaiseraugst), Novartis (Basel, Schweizerhalle), Lonza Group headquarters... Regional concentration affects valuations, as companies in established clusters benefit from supplier ecosystems, specialized talent pools, and industry networks.